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This open randomized, cross-over study compared the clinical efficacy and patient acceptability of the two 
bronchodilator delivery systems, terbutaline Turbuhaler@ (0.5 mg t.i.d.) and salbutamol Rotahale@ (0.4 mg 
t.i.d.), each given for 3 weeks. Thirty-two adult asthmatics (21 males and 11 females with a mean age of 34 
years) who demonstrated at least 15% reversibility in PEF or FEV, in response to terbutaline, were enrolled 
for study. The median reversibility in FEV, was 27.5% for the terbutaline-salbutamol group and 21% for the 
salbutamol-turbutaline group. Two patients discontinued during terbutaline treatment (one due to respiratory 
infection and one due to tachycardia, exhaustion and tremor) and five patients were lost to follow-up during 
salbutamol treatment, leaving data from 25 patients for an ‘all patients treated’ analysis. 
Mean morning PEF was 426 1 min - ’ during terbutaline and 410 1 min ~ i during salbutamol (difference 
16lmin-‘, 95% CI of difference 3-28 1 min - ‘, P=O.O16), and mean evening PEF was 446 1 min- ’ during 
terbutaline and 428 1 min ~ ’ during salbutamol (difference 18 1 min - ‘, 95% CI 5-30 1 min - ‘, P=O.O076). No 
significant differences were detected in diary symptom scores or in use of additional study drug during the day 
or night, and no serious adverse events were reported. When asked to state their treatment preferences on the 
basis of effects, side-effects and overall, more patients preferred Turbuhaler in each case, although no 
statistically significant differences were detected. 
In conclusion, terbutaline via Turbuhaler was significantly more effective than salbutamol via Rotahaler in 
controlling lung function (mean daily PEF) in adults with mild to moderate asthma, and it was the preferred 
treatment overall in 44% of patients, compared with 16% for Rotahaler (ns.). 
Introduction 
Inhalation is the preferred method of adminis- 
tration for most drugs used in the treatment of 
airflow obstruction. However, many patients do not 
obtain maximum benefit from such therapy because 
they are unable to use their pressurized aerosols 
efficiently (1). The most common problems en- 
countered involve the need to synchronize inhaler 
actuation with inspiration and it is for this reason 
that breath-actuated inhalers have been developed 
(2). Devices such as RotahalerQ require each dose of 
drug to be loaded in the form of a capsule containing 
drug and lactose carrier powder, whilst Turbuhalera 
is a device which dispenses pure drug without addi- 
tives, and is pre-loaded with 200 doses. In an acute 
cumulative dose-response study (3), 0.25 mg terbuta- 
line by Turbuhaler was found to be equivalent to 
0.2 mg salbutamol by Rotahaler. The purpose of 
this study was to compare the clinical efficacy 
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(measured as daily PEF, morning and evening) and 
patient acceptability of the two devices for chronic 
use in asthma treatment when loaded with ter- 
butaline 0.5 mg dose - ’ (Turbuhaler) or salbutamol 
0.4 mg dose - ’ (Rotahaler). 
Patients and Methods 
Thirty-two adult patients with chronic asthma, 
who were taking regular &agonist therapy, were 
recruited for study between September 1990 and 
March 1992. The inclusion criteria required a revers- 
ibility of at least 15% in FEV, or PEF after 
3 x 0.5 mg doses of terbutaline via Turbuhaler, and 
the patients had to be sufficiently stable not to have 
experienced a marked exacerbation of their asthma 
during the month prior to the study. Patients who 
were hypersensitive to terbutaline or salbutamol, or 
who had significant concomitant disease of any 
system, were excluded from study, as were those 
with current respiratory infection. Patients who had 
0 1996 W. B. Saunders Company Ltd 
206 D. Gioulekas et al. 
Table 1 Standardized checklists for evaluation of inhalation technique 
For Turbuhaler@ For Rotahalera 
Efficient technique Efficient technique 
Inhaler not loaded in upright ( f 45”) position Rotacap inserted incorrectly 
(e.g. not far enough in) 
Rotation sequence incorrect - no dose loaded Incorrect operation 
Air inlet holes covered during inspiration Capsule not separated by Rotahaler 
Inspiration through nose rather than mouth Inspiration through nose rather than mouth 
Exhalation through Turbuhaler Exhalation through inhaler 
Breath not held after inspiration Breath not held after inspiration 
Other, specify Other, specify 
previously used Rotahaler (Turbuhaler was not 
available commercially at the time of study) were also 
excluded. 
The study was designed as an open, randomized 
cross-over of two treatments: 0.5 mg terbutaline t.i.d. 
(via Turbuhaler) and 0.4mg salbutamol t.i.d. (via 
Rotahaler), each given for a period of 3 weeks. 
Additional doses of trial medication were allowed as 
required, provided they were recorded in the diary 
cards. 
Patients were asked to attend the clinic for assess- 
ment at entry and at the end of each treatment 
period. At the entry visit, demographic details and 
disease history were recorded and routine lung func- 
tion tests were performed, which included measure- 
ment of FEV,, FVC and PEF. The inhalation 
technique required for each delivery device was 
demonstrated in detail at the start of each treatment 
period and was then checked at the end of treatment 
using a standardized checklist (Table 1). Overall 
judgement of inhaler technique was then graded as 
‘excellent’ if the patient followed all instructions 
exactly and inhaled correctly, ‘adequate’ if the patient 
made no major errors in the sequence of instructions, 
but did not follow the sequence of instructions 
exactly (these patients did inhale correctly), and 
‘inadequate’ if the patient made a major error in the 
sequence of instructions, or had poor coordination 
or did not inhale correctly. Patients were supplied 
with diary cards and mini Wright peak flow meters 
(Clement Clarke International Ltd) to record morn- 
ing PEF (immediately after rising) and evening PEF 
(at bedtime) prior to study medication, and prefer- 
ably when &agonists had not been used during the 
previous 2 h. 
Patients were also asked to record their asthma 
symptoms at the same time on a scale where O=none, 
1 =mild, 2=moderate, 3=severe. Extra study drug 
consumption during the day and night (between PEF 
measurements) was also recorded. 
At the end of the study, patients were asked to 
state their treatment preference, if any, for one or 
other of the study treatments. Any adverse events 
experienced during the course of treatment were to be 
noted by patients in their diary cards and assessed 
jointly with the physician at the next clinic visit. If the 
event was severe or alarming, however, patients were 
requested to contact their doctor immediately. 
STATISTICAL ANALYSES 
It was calculated that data from 32 evaluable 
patients would detect, with 90% power, a true 
mean difference in PEF between the treatments of 
241min-’ using an estimated SD of 40 1 min - ‘, 
where SD is the corresponding standard deviation of a 
within-patient difference between the two treatments. 
This was based on a two-sided, paired t-test at the 5% 
significance level. As data were evaluable for only 
25 of the patients, the study power to detect this 
treatment difference was reduced to 80%. 
For each patient, the mean values of PEF, asthma 
symptom scores and the number of extra inhalations 
of study drug were calculated for each 3-week treat- 
ment period. Two sample t-tests were used to com- 
pare terbutaline and salbutamol, according to Jones 
and Kenward (4). Each analysis was tested (with a 
significance level of 10%) for period effect and for the 
presence of carry-over. The patient’s treatment 
preference (for effect, side-effects and overall) was 
analysed using Prescott’s test (4), and the investi- 
gator’s assessment of patient technique using the two 




Thirty-two patients (21 males and 11 females) with 
a mean age of 34 years (range 14-58) and asthma 
history of 8.6 years (range 0.3-23) were enrolled 
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Table 2 Mean PEF values (SD), expressed in 1 min - ’ for 
each treatment period 




95% CI of difference 
426 (117) 446 (130) 




in the study. Their mean FEV,, FVC and PEF at 
entry were 2.74 1, 3.61 1 and 408 1 min- I, respec- 
tively. Two patients, allocated to terbutaline- 
salbutamol, discontinued the study during 
terbutaline treatment; one due to tachycardia, 
exhaustion and tremor and one due to a respiratory 
infection. Five patients allocated to salbutamol- 
terbutaline were lost to follow-up during salbutamol 
treatment. An ‘all patients treated’ analysis was per- 
formed on data from the remaining 25 completed 
patients; 14 of whom received terbutaline-salbutamol 
and the remaining 11 received salbutamol- 
terbutaline. Mean baseline predicted FEV, was 70% 
for the terbutaline-salbutamol group and 75% for the 
salbutamol-terbutaline group. 
Regular concurrent medication for asthma was 
taken by some of the patients: inhaled steroids were 
continued in six patients (five on terb-salb and one 
on salb-terb), disodium cromoglycate in 15 patients 
(eight on terb-salb and seven on salb-terb) and four 
patients took oral theophylline (three on terb-salb 
and one on salb-terb). 
DAILY LUNG FUNCTION AND SYMPTOMS 
Mean morning PEF (AM PEF) and evening 
PEF (PM PEF) calculated for each 3-week treat- 
ment period are presented in Table 2. Both morning 
and evening PEF were significantly higher during 
terbutaline treatment than during salbutamol treat- 
ment (P=O.O16 for AMPEF and P=O.O08 for 
PM PEF). 
Mean symptom scores calculated from diary 
recordings over the same period were lower during 
terbutaline treatment than during salbutamol treat- 
ment, both during the daytime (0.4 vs. 0.55, n.s.) and 
during the night-time (0.52 vs. 0.65, n.s.). When 
intake of extra study medication was compared for 
the two treatment periods, there was no statistically 
significant difference. Nine patients required no res- 
cue treatment during terbutaline treatment compared 
with eight patients during the salbutamol treatment. 
INHALER TECHNIQUE AND PATIENT PREFERENCE 
According to the investigator’s assessment of 
patient inhaler technique, 19 patients demonstrated 
excellent (i.e. efficient) technique with Turbuhaler, 
compared with 15 patients who demonstrated excel- 
lent technique with Rotahaler (n.s.). The problems 
noted during the demonstration of each device by the 
patient are summarized in Table 3. 
When patients were asked to state their preference 
for one or other of the devices on the basis of effect, 
13 patients preferred Turbuhaler, eight preferred 
Rotahaler, and four said they were equal (n.s.). 
Comparing side-effects, 10 patients preferred Turbu- 
haler, one patient preferred Rotahaler, and 14 
patients said they were equal (n.s.). When patients 
were asked to give an overall preference for one or 
other treatment, 11 stated a preference for terbutaline 
Turbuhaler, four preferred salbutamol Rotahaler, 
and 10 said they were equal (n.s.). Preference is 
summarized in Fig. 1. 
Discussion 
The purpose of this study was to compare both the 
efficacy and the patient acceptability of broncho- 
dilator administered by Turbuhaler (terbutaline) and 
Rotahaler (salbutamol). It was also the intention to 
assess the patient preference for each device. This 
precluded the use of a double-blind study design 
where dummy inhalers are used simultaneously with 
each active treatment, as patients would not have 
known which device had given them symptomatic 
relief and their views concerning the ease of use of 
the devices might have been confounded by the in- 
convenience of having to use two devices on each 
Table 3 Problems noted during assessment by investigator of inhaler technique 
Turbuhaler@ 
Inhaler not loaded in upright position (1) 
Breath not held after inspiration (4) 
Rotation sequence incorrect (2) 
Rotahale@ 
Rotacap inserted incorrectly (6) 
Breath not held after inspiration (5) 



















Fig. I Patient preference for Turbuhaler@ or Rota- 
baler@. Solid bar, Turbuhaler; Open bar, Rotahaler; 
stippled bar, equal. 
occasion. These factors were considered to outweigh 
the inherent problems of the open design in this 
study. Hence, the study was performed as an open 
cross-over of the two treatments. 
The diary lung function data showed that patients 
had significantly higher morning and evening PEF 
during Turbuhaler therapy than during Rotahaler 
therapy, regardless of the treatment order taken. 
Similar differences in AM PEF were noted by Anani 
et al. (5) in a study of more severe asthmatic adults 
who took each drug four times a day. Stallaert (6) 
compared the two devices in adults using the same 
dosing frequency as in the present study, with admin- 
istration of each drug for 4 weeks. As in the Anani 
et al. study (5), significant differences were observed 
for AM PEF only. 
If a device preference existed in the present study, 
it tended to be preference for Turbuhaler (44%) 
rather than Rotahaler (16%) although this difference 
did not reach statistical significance. In other studies 
(S-lo), preference for Turbuhaler ranged from 50 to 
79% and for Rotahaler from 9 to 33%. The physi- 
cian’s assessment of inhaler technique in this study 
found that 76% of the patients demonstrated ‘excel- 
lent’ technique for Turbuhaler compared with 60% 
for Rotahaler. These results are very similar to those 
found in a large audit of inhalers (1 l), where 78% of 
the patients obtained the highest score for technique 
using Turbuhaler compared with 50% using Rota- 
baler. In a randomized study comparing five inhaler 
systems which included Turbuhaler and Rotahaler 
(lo), patients received a single instruction and 
demonstration of each device and were then assessed 
on their ability to use it correctly (defined as adequate 
preparation, coordination of actuation and breath- 
holding). The proportion of patients who used the 
device incorrectly, for one or more reasons, was 38% 
for Rotahaler compared with 0% for Turbuhaler. 
The ability of patients to use Turbuhaler so efficiently 
after only one demonstration provides convincing 
evidence that it is very simple to use, provided 
accurate instructions are given. The majority of the 
‘problems’ observed in Turbuhaler patients during 
this study did not concern the device itself, but the 
breath-holding at the end of inhalation. When this 
study was designed, breath-holding after inhalation 
was believed to be an important feature of good 
inhalation technique. Consequently, it was used in 
the checklist for assessment of technique. It has since 
been demonstrated, however, that this manoeuvre 
does not influence the bronchodilating effect of terbu- 
taline administered by Turbuhaler to adults (12). 
Thus, the ‘breath-holding’ problems noted with 
Turbuhaler in this study probably did not impede its 
efficacy, and this may explain why higher lung func- 
tion was noted with Turbuhaler. Some of the patients 
in the present study complained that they could not 
feel the medication when they inhaled from Turbu- 
haler. This problem has also been described previ- 
ously and it has been suggested by Crompton (13) 
that all patients for whom Turbuhaler is prescribed 
should be informed that they should not expect much 
taste or any sensation of drug entering their mouths. 
They are then less likely to perceive this feature of the 
medication as negative. 
In conclusion, this study demonstrated that terbu- 
taline via Turbuhaler was more effective than sal- 
butamol via Rotahaler in controlling lung function in 
adult patients with mild to moderate asthma. Both 
inhalation devices were well-accepted, with 44% 
of patients preferring Turbuhaler, 16% preferring 
Rotahaler and 40% stating no preference for either 
device (n.s.). 
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